Fundamental Analysis of ERYTECH PHARMA - SPON ADR(NASDAQ:ERYP) stock

Fundamental Rating

ERYP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of ERYP have multiple concerns. While showing a medium growth rate, ERYP is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ERYP had negative earnings in the past year.

ERYP had a negative operating cash flow in the past year.

In the past 5 years ERYP always reported negative net income.

ERYP had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ERYP has negative profitability rations, so we won't be analyzing them here.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ERYP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ERYP has about the same amount of shares outstanding.

The number of shares outstanding for ERYP has been increased compared to 5 years ago.

ERYP has a better debt/assets ratio than last year.

2.2 Solvency

ERYP has an Altman-Z score of -2.54. This is a bad value and indicates that ERYP is not financially healthy and even has some risk of bankruptcy.

ERYP has a Altman-Z score (-2.54) which is comparable to the rest of the industry.

A Debt/Equity ratio of 0.44 indicates that ERYP is not too dependend on debt financing.

ERYP has a Debt to Equity ratio of 0.44. This is in the lower half of the industry: ERYP underperforms 71.50% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF	N/A
Altman-Z	-2.54

ROIC/WACCN/A

WACC4.93%

2.3 Liquidity

A Current Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.

ERYP has a Current ratio of 3.65. This is in the lower half of the industry: ERYP underperforms 61.67% of its industry peers.

A Quick Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.

ERYP's Quick ratio of 3.65 is on the low side compared to the rest of the industry. ERYP is outperformed by 60.71% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	3.65
Quick Ratio	3.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.68% over the past year.

Looking at the last year, ERYP shows a very strong growth in Revenue. The Revenue has grown by 59.04%.

ERYP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.60% yearly.

EPS 1Y (TTM)99.68%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q102.44%

Revenue 1Y (TTM)59.04%

Revenue growth 3Y7.96%

Revenue growth 5Y14.6%

Revenue growth Q2Q198.12%

3.2 Future

Based on estimates for the next years, ERYP will show a very strong growth in Earnings Per Share. The EPS will grow by 26.28% on average per year.

Based on estimates for the next years, ERYP will show a very negative growth in Revenue. The Revenue will decrease by -44.77% on average per year.

EPS Next Y22.35%

EPS Next 2Y26.28%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year16.44%

Revenue Next 2Y16.85%

Revenue Next 3Y-56.11%

Revenue Next 5Y-44.77%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ERYP. In the last year negative earnings were reported.

Also next year ERYP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ERYP's earnings are expected to grow with 26.28% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y26.28%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ERYP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ERYTECH PHARMA - SPON ADR

NASDAQ:ERYP (6/28/2023, 7:00:02 PM)

0.78

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap26.61M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.17

Health

		Industry Rank	Sector Rank
Debt/Equity	0.44
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	3.65
Quick Ratio	3.65
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)99.68%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y22.35%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)59.04%

Revenue growth 3Y7.96%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ERYTECH PHARMA - SPON ADR (ERYP)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens